23 completed, 6 recruiting, 5 active not recruiting, 2 unknown. 38 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 38 | Completed 23, Recruiting 6, Active not recruiting 5, Unknown 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow Disorders of Sex Development: new trials by email Literature Review of Disorders of Sex Development trials Research Report on Disorders of Sex Development
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years Semaglutide (Wegovy) weekly injection, Placebo weekly Injection - Craniopharyngioma, Child | Phase 3 | Not yet recruiting | University Hospital, Angers | 50 | 2026-11-01 | 2026-09-29 |
| The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature Inpegsomatropin-Injection, Givopegsomatropin Solution Injection - Turner Syndrome | Phase 3 | Recruiting | Xiamen Amoytop Biotech Co., Ltd. | 84 | 2026-07-05 | 2026-07-22 |
| A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) Atumelnant, Placebo - Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | Phase 2 / Phase 3 | Recruiting | Crinetics Pharmaceuticals Inc. | 153 | 2026-01-22 | 2026-11-10 |
| Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector - Turner Syndrome, Short Stature Homeobox Gene Mutation | Phase 3 | Recruiting | Ascendis Pharma A/S | 186 | 2025-12-12 | 2026-11-05 |
| A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia Atumelnant, Placebo - Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | Phase 3 | Recruiting | Crinetics Pharmaceuticals Inc. | 150 | 2025-12-11 | 2026-11-10 |
| A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) Setmelanotide, Placebo - Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form | Phase 3 | Recruiting | Rhythm Pharmaceuticals, Inc. | 39 | 2025-09-23 | 2026-02-12 |
| Open-Label Extension Study of Setmelanotide Setmelanotide - Obesity Associated With Defects in Leptin-melanocortin Pathway | Phase 3 | Completed | Rhythm Pharmaceuticals, Inc. | 28 | 2024-10-21 | 2026-07-15 |
| A Trial of Setmelanotide in Acquired Hypothalamic Obesity Setmelanotide, Placebo - Hypothalamic Obesity | Phase 3 | Active not recruiting | Rhythm Pharmaceuticals, Inc. | 143 | 2023-04-26 | 2026-08-10 |
| Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome Anastrozole, Semaglutide, human chorionic gonadotropin - Klinefelter Syndrome | Phase 3 | Recruiting | Georgios Papadakis | 150 | 2023-03-21 | 2026-05-11 |
| A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9 Somapacitan - SGA, Turner Syndrome | Phase 3 | Active not recruiting | Novo Nordisk A/S | 47 | 2023-02-01 | 2026-08-13 |
| A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow Somapacitan, Norditropin® - SGA, Turner Syndrome, Noonan Syndrome, ISS | Phase 3 | Active not recruiting | Novo Nordisk A/S | 412 | 2022-08-10 | 2026-06-12 |
| Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia Chronocort, Cortef, Placebo - Congenital Adrenal Hyperplasia | Phase 3 | Completed | Neurocrine UK Limited | 55 | 2022-05-24 | 2026-10-02 |
| Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia Chronocort - Congenital Adrenal Hyperplasia | Phase 3 | Completed | Immedica Pharma AB | 76 | 2022-04-01 | 2026-06-18 |
| Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study) Crinecerfont, Placebo - Congenital Adrenal Hyperplasia | Phase 3 | Active not recruiting | Neurocrine Biosciences | 103 | 2021-06-25 | 2025-02-05 |
| Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study Testosterone gel, Placebo - Disorder of Sex Development, 46,XY | Phase 3 | Unknown | Erasmus Medical Center | 1 | 2021-06-01 | 2021-04-05 |
| Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia Crinecerfont, Placebo - Congenital Adrenal Hyperplasia | Phase 3 | Active not recruiting | Neurocrine Biosciences | 182 | 2020-12-16 | 2026-05-11 |
| Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy Chronocort®, Standard Care - Congenital Adrenal Hyperplasia | Phase 3 | Withdrawn | Neurocrine UK Limited | 2018-10-04 | 2026-09-14 | |
| Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Exenatide, Placebo - Craniopharyngiomas, Hypothalamic Obesity | Phase 3 | Completed | University Hospital, Bordeaux | 42 | 2017-01-11 | 2026-05-22 |
| A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH Hydrocortisone - Congenital Adrenal Hyperplasia | Phase 3 | Completed | Neurocrine UK Limited | 91 | 2016-08-18 | 2026-10-02 |
| Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity Exenatide, placebo - Hypothalamic Obesity | Phase 3 | Completed | Seattle Children's Hospital | 42 | 2016-03-01 | 2022-05-05 |
Showing 20 of 38. Sign in to see all of them.
Turner Syndrome (14) · Adrenal Hyperplasia, Congenital (11) · Sexual Infantilism (6) · Dwarfism (4) · Genetic Diseases, Inborn (3) · Infertility (3) · Noonan Syndrome (3) · Craniopharyngioma (2) · Failure to Thrive (2) · Hyperandrogenism (2) · Hypogonadism (2) · Klinefelter Syndrome (2) · Obesity (2) · Polycystic Ovary Syndrome (2)
Congenital Abnormalities (38) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (38) · Female Urogenital Diseases (38) · Female Urogenital Diseases and Pregnancy Complications (38) · Gonadal Disorders (38) · Male Urogenital Diseases (38) · Urogenital Abnormalities (38) · Urogenital Diseases (38) · Endocrine System Diseases (37) · Genetic Diseases, Inborn (25) · Gonadal Dysgenesis (20) · Chromosome Disorders (15) · Sex Chromosome Disorders (15) · Sex Chromosome Disorders of Sex Development (15)
Human Growth Hormone (7) · Hydrocortisone (5) · setmelanotide (3) · Dexamethasone (2) · Estradiol (2) · Exenatide (2) · Growth Hormone (2) · Prednisolone (2) · Prednisone (2) · asenapine (2) · crinecerfont (2) · semaglutide (2) · somapacitan (2) · Anastrozole (1) · Androgens (1)
Novo Nordisk A/S (5) · Neurocrine UK Limited (4) · Rhythm Pharmaceuticals, Inc. (3) · Crinetics Pharmaceuticals Inc. (2) · Eli Lilly and Company (2) · Neurocrine Biosciences (2) · Organon and Co (2) · 59th Medical Wing (1) · Ascendis Pharma A/S (1) · Dong-A ST Co., Ltd. (1) · Erasmus Medical Center (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Ferring Pharmaceuticals (1) · Georgios Papadakis (1) · Immedica Pharma AB (1)
United States (22) · France (13) · United Kingdom (9) · Germany (8) · Italy (8) · Netherlands (8) · Spain (7) · Canada (6) · Poland (6) · Belgium (5) · Japan (5) · Greece (4) · South Korea (4) · Austria (3) · Brazil (3)
David Meeker, MD (3) · Andrea Isidori, MD, PhD (1) · Andrea Lenzi, MD (1) · Blandine Gatta-Cherifi, Pr (1) · Byung Kyu Suh, M.D., Ph.D. (1) · Chang Jong Kim, M.D., Ph.D. (1) · Cheol Woo Ko, M.D., Ph.D. (1) · Choong Ho Shin, M.D., Ph.D. (1) · Christian Roth, MD (1)
PMID 26091193, PMID 33527139, PMID 15784709, PMID 16757526, PMID 20733274, PMID 21619701, PMID 31532522, PMID 34893062, PMID 38450721, PMID 38828945, PMID 38828955, PMID 39672600, PMID 41712606, PMID 41774755, PMID 42418774, PMID 42528856, PMID 42821228
2009 (2), 2023 (2), 2004 (1), 2019 (1)